Proxsys Rx

APRIL 1, 2025

Maximizing pharmacys role in your hospitals revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. Recent estimates indicate that hospitals and clinics collectively lose around $3.2 Additionally, up to $8.4

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Documentation Drug Pricing 52

Drug Channels

AUGUST 6, 2024

I then document how five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market. Click here if you can’t see the video below.

Drug Pricing 90

Drug Pricing Documentation Hospitals 90

Drug Channels

MARCH 15, 2022

drug pricing, reimbursement, and dispensing system. There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities. The 2022 Economic Report on U.S. The report has been thoroughly updated with the latest data and includes loads of new material and new sections.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing Documentation 98

Drug Channels

JULY 21, 2020

Last week, I documented that nearly half of U.S. pharmacies now participate in the 340B Drug Pricing Program. Hospitals are the primary 340B covered entities that engage with these specialty pharmacies. Below, we update our exclusive analysis of the biggest specialty pharmacies within 340B.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Documentation Hospitals 52

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). This includes collecting data on utilization management practices, formulary changes, and patient experiences.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Pharmaceutical Technology

JANUARY 6, 2023

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. Gilenya is an oral medication for multiple sclerosis.

Documentation 97

Documentation Hospitals Dosage Drug Pricing 97

Proxsys Rx

APRIL 19, 2024

Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. Either way, I see even more confusion coming, where 340B manufacturer restrictions are concerned.” The Supreme Court voted unanimously to reverse 340B cuts.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52